|
 |
VelcadeThis page contains recent news articles, when available, and an overview of Velcade but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.O medicamento Velcade®, usado para tratar a segunda forma mais comum de cancro do sangue, pode agora conter no rótulo que aumenta a sobrevida dos pacientes ... POP - Portal de Oncologia Portugês Survival data OK for cancer drug Velcade's label - Jan 4, 2010 NEW YORK, Jan 4 (Reuters) - The drug Velcade used to treat the second most common form of blood cancer can now state on its label that it has led to longer ... Reuters Survival data OK for cancer drug Velcade's label - Jan 4, 2010 NEW YORK, Jan 4 (Reuters) - The drug Velcade used to treat the second most common form of blood cancer can now state on its label that it has led to longer ... Reuters India Velcade-Thalidomide-Dexamethasone Treatment Is Promising For Newly Diagnosed ... - Dec 30, 2009 At the recent American Society of Hematology (ASH) annual meeting, there were several presentations comparing a drug regimen of Velcade (bortezomib), ... The Myeloma Beacon Velcade® Consolidation Improves Response Rate After High-dose Melphalan for ... - Dec 21, 2009 ...[1] Velcade is the first in a new class of anticancer agents known as proteasome inhibitors and is being evaluated in clinical trials for the treatment of ... Cancer Consultants ASH data favour maintenance therapy with Revlimid, Velcade - Dec 10, 2009 Efforts to position the blood cancer drugs Revlimid (lenalidomide, Celgene) and Velcade (bortezomib, Takeda/Johnson & Johnson) for earlier intervention and ... Pharma Times Tanespimycin-Velcade Combination Proves Highly Effective In Multiple Myeloma ... - Dec 14, 2009 One of the ASH presentations showed that the combination treatment of tanespimycin and Velcade (bortezomib) effectively targets Hsp90 in patients with ... The Myeloma Beacon Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite ... - Jan 1, 2010 ...and Doxil plus Velcade (bortezomib); thalidomide and dexamethasone; thalidomide and dexamethasone plus Velcade; or a combination of Velcade, melphalan, ... The Myeloma Beacon NPI-0052 Shows Promise In Treating Relapsed/Refractory Multiple Myeloma (ASH 2009) - Dec 28, 2009 Found in marine bacteria, NPI-0052 acts, like Velcade, as a proteasome inhibitor. Both compounds prevent enzymes in cancer cells that regulate growth from ... The Myeloma Beacon Oncology R&D Challenges & Opportunities - Dec 29, 2009 Its flagship product is VELCADE (bortezomib) for Injection, an FDA-approved treatment for multiple myeloma and relapsed mantle cell lymphoma. ... Life Science Leader Magazine Perifosine Combination Therapy Is Promising For Relapsed And Refractory ... - Dec 17, 2009 Results from recent Phase 1/2 clinical trials show that a perifosine, Velcade (bortezomib) and dexamethasone (Decadron) combination treatment is safe and ... The Myeloma Beacon VELCADE(R) (bortezomib) Added to Standard Melphalan-Prednisone Therapy ... - Dec 11, 2009 Data from a long-term, Phase 3 trial in patients newly diagnosed with multiple myeloma showed that the addition of VELCADE(R) (bortezomib) to the current ... AUTO-MOBI.info Novel Therapeutic Agents May Improve Kidney Impairment In Newly Diagnosed ... - Dec 26, 2009 Group C patients received treatment with Velcade (bortezomib) and dexamethasone. Patients treated with novel therapeutic agents experienced the greatest ... The Myeloma Beacon Zolinza Combination Treatments Offer Benefit For Multiple Myeloma Patients ... - Dec 22, 2009 Nine patients (median age of 56) with relapsed or refractory myeloma enrolled in this study, receiving 1.3mg/m² of Velcade on days 1, 4, 8, and 11, ... The Myeloma Beacon Treatment Updates - Dec 23, 2009 The key findings from a phase 3 Spanish study are three-fold: less aggressive initial (induction) therapy with once-weekly—rather than twice-weekly—Velcade ... Curetoday.com (press release) Æterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with ... - Dec 16, 2009 The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib (Velcade(R)) and ... CNNMoney.com (press release) Beneficial BrewCan green tea prevent cancer? - Dec 23, 2009 In June, a study published in the journal Blood found that EGCG may counteract the effects of Velcade (bortezomib), an approved treatment for multiple ... Curetoday.com (press release) $365M Deal Hands Millennium Ex-US Rights for CD30 Drug - Dec 16, 2009 He noted that Millennium's pipeline includes 17 oncology molecules, led by its flagship drug Velcade (bortezomib), a first-in-class molecule approved to ... BioWorld Online Dendreon Nails Down $409M, Stewart Parker Gets Itch to Return, Seattle ... - Dec 16, 2009 ...retains full commercial rights in the US and Canada, and has found a partner with a lot of experience in blood cancers with bortezomib (Velcade). ... Seattle Post Intelligencer Revlimid® Delays Progression of Multiple Myeloma After Stem Cell Transplantation - Dec 21, 2009 All received induction therapy with Velcade® (bortezomib) , dexamethasone, and Adriamycin® (doxorubicin) followed by tandem autologous stem cell transplants ... Cancer Consultants Adult T-cell Leukemia/ Lymphoma: Complexities in Diagnosis and Novel Treatment ... - Dec 17, 2009 ...including the novel antifolate pralatrexate (Folotyn), the proteasome inhibitor bortezomib (Velcade), and deacetylase inhibitors such as romidepsin ... Cancer Network How Much To Extend Life? Allos Therapeutics Says $30000 per Month - Dec 14, 2009 ...including blockbuster drugs oncologists are already comfortable with in other blood cancer — like Velcade (bortezomib) and vorinostat, ... BNET More Good News for Myeloma Patients Could Change Patterns of Treatment - Dec 18, 2009 ...benefits at three years and beyond using continuous REVLIMID, and long-term benefits from maintenance with another new targeted drug, VELCADE ® . ... PharmaLive.com (press release) Æterna Zentaris: son partenaire Keryx lance une étude d'enregistrement de ... - Dec 16, 2009 L'étude intitulée, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib (Velcade(R)) and ... CNW Telbec (Communiqué de presse) 国家食å“?è?¯å“?监ç?£ç®¡ç?†å±€2009å¹´ - Dec 23, 2009 ...å?·ï¼‰çš„文件è¦?求，我局对æ?¥ä»¶ä¸æ??å?Šçš„43家网站进行了彻底清查，ç»?查è¯?，43家网站å?‡å˜åœ¨è¿?æ³•å®£ä¼ æˆ–é”€å”®â€œæ³¨å°„ç”¨ç¡¼æ›¿ä½?ç±³â€?（商å“?å??：万ç?‚（Velcade））的行为。 ... 中国食品商务网 המכון לרפו×?×” ב×?רה"ב - כך ממסחרי×? ידע ב-2.3 מילי×?רד דולר - Dec 30, 2009 ...בין ×?לה × ×™×ª×Ÿ לכלול ×?ת בדיקת ×”-BRCA1 לסרטן השד, חיסון ×”-Harvix × ×’×“ צהבת × ×’×™×¤×™×ª, ×¡×˜× ×˜ הטקסוס של בוסטון ×¡×™×™× ×˜×™×¤×™×§, התרופה לסרטן Velcade ועוד רבי×? ×?חרי×?. ... גלובס Les analystes: le point sur Stella-Jones, Transat et Aeterna - Dec 17, 2009 Il note cependant que des sociétés comme Takeda/Millenium et Celgene ont réussi avec des produits tels que Velcade et Revlimid, ce qui vient mitiger le ... Canoë Canarias consume más medicamentos que Bolivia - Dec 12, 2009 ...donde el Instituto para la Salud y Excelencia ClÃnica de Inglaterra y Gales (NICE) y la compañÃa farmacéutica productora del Velcade –un tratamiento ... La Opinión de Tenerife Velcade Data Boost Millennium Pharma - Sep 18, 2007 Millennium Pharmaceuticals(MLNM Quote) on Tuesday halted a phase III trial in light of positive interim results for its Velcade in patients with newly ... TheStreet.com - TheStreet.com (subscription) Millennium confident in its 2008 Velcade forecast - Jan 9, 2008 By Lisa Baertlein. SAN FRANCISCO, Jan 9 (Reuters) - Millennium Pharmaceuticals Inc MLNM.O said on Wednesday that the company has a "high level of ... Reuters Millennium reports positive results from VELCADE Phase III Trials … - Dec 10, 2007 ATLANTA (Thomson Financial) - Millennium Pharmaceuticals Inc (nasdaq: MLNM - news - people ) said results from the Phase III VISTA trial, which compared ... Forbes New drug shows promise in treating multiple myeloma - Jun 15, 2005 Velcade, a new type of drug to treat the bone marrow cancer multiple ... Velcade made cancers disappear in 6% of patients; dexamethasone produced such ... USA Today Millennium shares fall on Velcade outlook - Jan 4, 2008 NEW YORK, Jan 4 (Reuters) - Millennium Pharmaceuticals Inc MLNM.O on Friday projected US sales growth of 20 percent to 30 percent in 2008 for its flagship ... Reuters FDA OKs Wider Use of Velcade - Jun 23, 2008 Japanese pharmaceutical company Takeda said late Friday that the Food and Drug Administration approved Velcade for patients with previously untreated ... TheStreet.com - TheStreet.com (subscription) Millennium Pharmaceuticals says Velcade combination study shows … - Jun 21, 2006 Millennium Pharmaceuticals Inc. of Cambridge said today a study showed that its multiple myeloma treatment Velcade was effective in combination with two ... Boston Globe Millennium Pharma sees $40M Velcade-related milestone payment from … - Dec 28, 2007 BOSTON (Thomson Financial) - Millennium Pharmaceuticals Inc. said Friday it expects to receive a $40 million payment from Ortho Biotech Products LP related ... Forbes Millennium shares jump on higher hopes for Velcade - Jan 2, 2008 BOSTON, Jan. 2 (Reuters) - Shares of Millennium Pharmaceuticals Inc MLNM.O rose as much as 10 percent on Wednesday amid optimism that sales of its cancer ... Reuters Millennium CEO very optimistic on Velcade growth - Nov 15, 2007 By Lisa Baertlein. NEW YORK (Reuters) - Millennium Pharmaceuticals Inc MLNM.O Chief Executive Deborah Dunsire on Thursday said the company is upbeat on 2008 ... Reuters UK Takeda wins US OK for expanded Velcade use - Jun 21, 2008 LOS ANGELES, June 20 (Reuters) - Takeda Pharmaceutical Co (4502.T) won US approval to promote its cancer drug Velcade for earlier treatment of multiple ... Reuters UK FDA to decide whether to expand uses for Velcade - Aug 9, 2006 The FDA has granted priority review toward expanding the use of Millennium Pharmaceuticals Inc.' cancer treatment Velcade. Federal regulators granted the ... Bizjournals.com Millennium, Celgene Fall - Jan 10, 2005 Sales of its Millennium's multiple myeloma treatment Velcade were up 51% to $44.8 ... The company says Velcade is the only drug with a significant survival ... TheStreet.com - TheStreet.com (subscription) Cancer drug Velcade might work in lupus: study - Jun 8, 2008 LONDON (Reuters) - Velcade, a drug used to treat cancer, might also work against the chronic autoimmune disease lupus, German researchers said on Sunday. ... Reuters UK Millennium asks FDA to approve cancer drug Velcade for new use - Jun 9, 2006 Millennium Pharmaceuticals Inc. wants the FDA to approve expanded treatment options for its cancer drug Velcade. The Cambridge, Mass., company said on ... Bizjournals.com Millennium to present new Velcade data - May 29, 2007 Millennium Pharmaceuticals Inc. said that it will present new data for the cancer drug Velcade at an oncology conference set to begin Friday. ... Boston Globe Cancer drug ban a death sentence, say sufferers - Jul 26, 2006 Velcade, also called bortezomib, is recommended for use in Scotland, ... Velcade was licensed in 2004 and hundreds of patients and their families have ... Telegraph.co.uk Millennium Maps Out Cost-Cuts - Oct 27, 2005 Velcade sales in the US rose 35% to $50.9 million in the quarter, ... Velcade is approved by the Food and Drug Administration for the blood cancer multiple ... TheStreet.com - TheStreet.com (subscription) Millennium expands Velcade tests - Aug 15, 2007 Millennium Pharmaceuticals Inc. said today that it has started a test to evaluate using Velcade in combination with other drugs. ... Boston Globe Millennium wins speedy review for new Velcade use - Jan 30, 2008 NEW YORK, Jan 30 (Reuters) - US regulators will review on a priority basis Millennium Pharmaceuticals Inc's MLNM.O Velcade as a treatment for patients with ... Reuters … unleashes raft of results for cancer drug Velcade - Jun. 28, 2007 - Jun 28, 2007 Its drug Velcade could be next contender for first-line treatment of multiple myeloma; company weighs competition vs. combo with Celgene's Revlimid. ... CNNMoney.com Millennium accelerates bid to expand Velcade use - Apr 18, 2006 Millennium Pharmaceuticals Inc. has launched a late-stage human clinical trial more quickly than expected in a bid to expand the use of Velcade to treat ... Bizjournals.com Takeda's Velcade Found Better Than Standard Drug - Aug 27, 2008 By Kanoko Matsuyama. Aug. 27 (Bloomberg) -- Takeda Pharmaceutical Co.'s Velcade helped keep the blood cancer multiple myeloma at bay in newly diagnosed ... Bloomberg Millennium's Velcade Wins Expanded US Clearance - Oct 15, 2007 By Jeffrey Tannenbaum. Oct. 15 (Bloomberg) -- Millennium Pharmaceuticals Inc.'s multiple myeloma drug Velcade won US Food and Drug Administration approval ... Bloomberg Ontario myeloma patients want their drug funded - Jul 24, 2005 But a drug called Velcade has been shown to batter it into remission for about 18 ... Health Canada approved Velcade in January and every other province but ... CTV.ca Velcade Cancer Study Begins - Mar 6, 2006 By Althea Chang. Millennium Pharmaceuticals (MLNM - commentary - Cramer's Take) and its partner Johnson & Johnson (JNJ - commentary - Cramer's Take) have ... TheStreet.com - TheStreet.com (subscription) Takeda to pay $8.8 billion for Millennium - Apr 10, 2008 According to Thomas Weisel analysts, Velcade has a very promising future. "Velcade is the prized asset in the transaction," they wrote in a research note. ... MarketWatch Cancer man plea for 'costly' drug - Dec 13, 2005 His doctor recommended for him the drug, Velcade. But Southampton University Hospitals Trust "considered the likelihood of it working" and cancelled his ... BBC News Velcade sales pare Millennium's loss - Nov 2, 2007 Biotechnology company Millennium Pharmaceuticals Inc. narrowed its loss in the third quarter, as stronger US sales from its cancer drug Velcade helped drive ... Boston Globe … Enter into US Co-Promotion Agreement for VELCADE(R)(bortezomib)... - Oct 26, 2006 ..."With this expanded educational effort behind VELCADE, we believe clinicians ... Millennium will pay a percentage of the VELCADE related costs for the Ortho ... Free with registration - PR Newswire - AccessMyLibrary.com Velcade ups lymphoma survival - Jun 4, 2007 CHICAGO, June 4 (UPI) -- Adding bortezomib -- Velcade -- to standard treatment achieved a one-year, 100 percent overall survival rate in lymphoma, ... United Press International Shift Seen Atop Millennium Pharmaceuticals - Jun 29, 2005 It has two drugs on the market, Integrilin, for acute coronary syndrome, and Velcade, for multiple myeloma. Revenues from drug sales and alliances were $448 ... New York Times FDA OKs Wider Use of Velcade - Jun 20, 2008 However, Robert Baird analyst Christopher Raymond noted on Monday that Velcade's label, although anticipated, is surprisingly broad. Velcade was approved ... TheStreet.com - TheStreet.com (subscription) Event Brief of Q1 2006 Millennium Pharmaceuticals Earnings Conference... - Apr 27, 2006 VELCADE: 1. US net product sales of VELCADE were $53.4m, an increase of 19% over ... s quarterly usage survey conducted in Feb., VELCADE continues to be the ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Studies of VELCADE(R) (Bortezomib) for Injection Show Emerging Role … - Apr 13, 2005 CAMBRIDGE, Mass., April 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the presentation of positive clinical results for ... RedOrbit Bloomberg Printer-Friendly Page - Apr 10, 2008 ..."VELCADE sales continue to strengthen, driven primarily by greater use in patients with ... VELCADE is being co-developed by Millennium Pharmaceuticals, ... Bloomberg Millennium Pharma Outlook: 'The Worst Is Over' - Jul 25, 2005 ..."Nonetheless, we acknowledge that the current stock price positions Millennium for outperformance should Velcade begin to look like a winner in an ... Forbes Celgene Might Be Trouble for Millennium - Apr 26, 2006 He's looking for Millennium to report flattish Velcade sales for the third quarter in a row and a loss of 4 cents a share, compared with the average Wall ... TheStreet.com - TheStreet.com (subscription) Hematology drugmakers rise on buyout news, drug data - Dec 10, 2007 The study is comparing Millennium's drug Velcade against Celgene Corp. ... Velcade is already approved for the treatment of multiple myeloma and mantle ... MarketWatch Bloomberg Printer-Friendly Page - Mar 13, 2008 ..."We are confident that VELCADE will be a key component of the standard of care in this ... VELCADE is being co-developed by Millennium Pharmaceuticals, ... Bloomberg FDA Approves Velcade® for Second Line Treatment of Myeloma - Mar 25, 2005 On March 25, 2005 the US Food and Drug Administration (FDA) announced the approval of Velcade® (bortezomib) for second-line therapy for patients with ... Cancer Consultants Medical apartheid as English cancer patients are denied life-extending... - Oct 20, 2006 Velcade is just the latest drug to be rejected in England when it is available ... The Velcade ruling is just the latest in a succession of decisions where ... Daily Mail Patients' anger at drug decision - Aug 30, 2007 The so-called Velcade Three, Janice Wrigglesworth, Jacky Pickles and Marie ... Velcade slows progression of myeloma - a cancer of bone marrow plasma cells. ... BBC News Drugmaker to refund NHS when its medicine fails - Jun 4, 2007 ...the National Institute for Health and Clinical Excellence (NICE), the Government's health adviser, proposed today to fund a cancer treatement, Velcade, ... Times Online VELCADE(R) (Bortezomib) for Injection Continues to Show Impressive … - Dec 12, 2005 ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the results from phase II studies evaluating the efficacy and ... RedOrbit … Patients Respond to Retreatment with Velcade(R) (Bortezomib) for … - Dec 14, 2006 ORLANDO, FL -- December 14, 2006 -- Millennium Pharmaceuticals, Inc. announced findings from two retrospective analyses evaluating Velcade(R)(bortezomib) ... DG News EU agency recommends extended use of Velcade - Jul 25, 2008 LONDON, July 25 (Reuters) - The European Medicines Agency has recommended extended use of Takeda Pharmaceutical Co (4502.T) and Johnson & Johnson's (JNJ. ... Reuters UK Millennium to Discuss Full Approval of VELCADE(R) (bortezomib) for … - Mar 28, 2005 CAMBRIDGE, Mass., March 28 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that the Company will be focusing on the recent full ... Free with registration - PR Newswire - AccessMyLibrary.com Hewitt faces fury of cancer patients 'given death penalty' - Sep 28, 2006 She was diagnosed with cancer five years ago and was given Velcade in a ... Velcade would allow her more time to see her son, Sean, start his career as a ... Telegraph.co.uk EU body warns against Velcade use in some patients - Mar 20, 2008 LONDON, March 20 (Reuters) - The European Medicines Agency has recommended that Millennium Pharmaceuticals Inc's MLNM.O cancer drug Velcade should not be ... Reuters Velcade Three welcome NHS scheme - Jun 4, 2007 Three women who launched a legal battle in a bid to receive a life-extending bone marrow cancer drug have welcomed a new scheme to make it more available. ... BBC News Velcade for injection multiple myeloma re-treatment clinical trial... - Mar 10, 2005 Millennium Pharmaceuticals Inc announced the initiation of EVEREST (Evaluation of Velcade Employed as Re-treatment for Efficacy, Safety and Tolerability). ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive … - Dec 8, 2006 CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has ... Free with registration - PR Newswire - AccessMyLibrary.com Velcade Data Boost Millennium Pharma - Jul 26, 2007 The fact that the trial met the efficacy endpoints early on, prompting the data-monitoring committee to recommend stopping the study can only be interpreted ... TheStreet.com - TheStreet.com (subscription) Millennium Reports First Quarter VELCADE(R) (Bortezomib) for Injection... - Apr 28, 2005 CAMBRIDGE, Mass., April 28 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported consolidated financial results for the quarter ended ... RedOrbit FDA Approves VELCADE(R) (Bortezomib) For Injection For Aggressive … - Dec 9, 2006 Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the US Food and Drug Administration (FDA) has granted full approval of VELCADE for the ... Medical News Today - Medical News Today (press release) Takeda to Buy Millennium Pharma for $8.8 Billion - Apr 10, 2008 Velcade, for rare blood cancers, generated more than $800 million last year as a ... Millennium anticipates US approval by June to promote Velcade as an ... Bloomberg Millennium says to keep costs in line with growth - Jan 8, 2007 N) to co-promote Velcade. The CEO said final data could be available this year from ... In addition to Velcade, the company has several experimental drugs, ... Reuters Velcade campaigner 'will fight on for all' - Oct 24, 2007 By Clive White ». A campaigning cancer sufferer thrown a lifeline by a health watchdog has pledged that the battle to get the treatment available to all ... Bradford Telegraph Argus Pricing Pills by the Results - Jul 14, 2007 Johnson & Johnson's money-back proposal on Velcade, known generically as ... Cancer patients protested, led by the Velcade Three — three Yorkshire women ... New York Times Millennium to test Velcade on rare form of cancer - Jan 10, 2005 Millennium Pharmaceuticals Inc. has launched a late-stage human clinical trial in a continued aggressive effort to expand the market for Velcade, ... Boston Business Journal Millennium Pharma: FDA OKs Velcade use in kidney disorders - Oct 15, 2007 Oct 15 (Reuters) - Millennium Pharmaceuticals Inc MLNM.O said US health regulators approved the use of its cancer drug Velcade, without dose adjustments, ... Reuters Patient anger at cancer 'lottery' - Aug 13, 2007 John McNamara, 47, from Harrogate, has been refused the drug Velcade for his bone ... Velcade is known to prolong patients' lives by up to five years and a ... BBC News Cancer patient wins drug appeal - Aug 16, 2007 An NHS trust which refused to supply the drug Velcade to a terminal cancer sufferer ... John McNamara, 47, from Harrogate, had been refused Velcade by North ... BBC News Bloomberg Printer-Friendly Page - May 16, 2008 The data will highlight the significant efficacy of multiple VELCADE based ... VELCADE is currently the market leader in relapsed multiple myeloma and the ... Bloomberg VELCADE(R) (Bortezomib) for Injection Addressed Disease-Related … - Jun 28, 2007 KOS, Greece, June 28 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported on data presentations of VELCADE that showed improved ... Free with registration - PR Newswire - AccessMyLibrary.com TheStreet.com Staff Reporter - Jan 5, 2007 ..."We expect an increase in Velcade sales throughout the year, but we wouldn't go as far as to call it flat" at the beginning of the year, ... TheStreet.com - TheStreet.com (subscription) Addition of VELCADE(R) (Bortezomib) for Injection Improved Survival... - Jun 4, 2006 ATLANTA, June 4 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the final results from a Phase II study conducted by the ... RedOrbit … Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib) for... - Dec 11, 2005 ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced extended survival data from the international, multi-center ... Free with registration - PR Newswire - AccessMyLibrary.com VELCADE(R) (Bortezomib) for Injection Based Induction Therapy … - Jul 2, 2007 CAMBRIDGE, MA -- (MARKET WIRE) -- 07/02/07 -- Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM) today reported that new data were presented on the comparative ... Web Services Journal - Web Services Journal New Data to Support VELCADE(R) (Bortezomib) For Injection Based … - Nov 26, 2007 CAMBRIDGE, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that new data from more than 130 abstracts of VELCADE ... RedOrbit VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers … - May 31, 2008 CHICAGO , May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 ... Genetic Engineering News - Genetic Engineering News (press release) VELCADE(R) (bortezomib) Findings Reinforce Efficacy and Survival … - Dec 9, 2008 Janssen-Cilag today announced preliminary results from a prospective, international, multicenter, open-label, phase II study showing re-treatment with ... ots.at Celgene 2nd-quarter profit jumps on Revlimid sales - Jul 24, 2008 T: Quote, Profile, Research) Velcade won US approval as an initial ... "What the numbers imply is Velcade is not having a material impact," Somaiya said. ... Reuters UK Millennium: Positive Velcade Phase III Results In New MM - Sep 19, 2007 By Randall Osborne. The early stop thanks to efficacy of Millennium Pharmaceuticals Inc.'s Phase III trial with Velcade in new multiple myeloma patients ... BioWorld Online - BioWorld Online Millennium to Webcast Business Update In Advance of 24th Annual … - Jan 6, 2006 VELCADE US net product sales are forecasted to be in the range of 225 to 250 ... As you will recall at our analysts day, we announced VELCADE milestones are ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Millennium Pharmaceuticals Q1 loss narrows; gives view - Apr 26, 2007 Millennium expects 2007 sales of Velcade of $240 million to $260 million. For the latest first quarter, the company posted a net loss of $6.8 million, ... Reuters Millennium Pharma Lives Up to Flat Expectations - Jul 26, 2007 The company's staple product, Velcade, which is approved in more than 80 countries, is being co-developed by Millennium Pharmaceuticals and Johnson ... TheStreet.com - TheStreet.com (subscription) Pay-For-Performance Pharmaceuticals: Satisfaction Guaranteed or Your ... - Jul 16, 2007 After a British health advisory group said that cancer drug Velcade was too expensive for the government to cover, Johnson & Johnson — the drug's ... Wired News Velcade (bortezomib) for Injection shows promising activity in two... - Feb 1, 2005 Millennium Pharmaceuticals Inc announced results from two clinical trials with Velcade (bortezomib) in patients with non-Hodgkin's lymphoma (NHL) published ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com EU-cleared cancer drug seeks NHS approval - Jun 20, 2007 Another drug, Velcade, is still undergoing final appraisal by Nice. ... Mr Low said: "Velcade received its EU licence in 2004, but here we are in 2007 still ... Telegraph.co.uk Velcade(R) (Bortezomib) for Injection Receives European Marketing … - Apr 28, 2005 Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has approved the use of VELCADE(R) (bortezomib) ... Free with registration - PR Newswire Europe - AccessMyLibrary.com Private patients to get drug NHS won't pay for - Jul 29, 2006 Velcade, also called bortezomib, continues to be available on the NHS in ... The insurer PPP has been paying for Velcade for use in multiple myeloma since ... Telegraph.co.uk Cancer victim selling home in drugs battle - Jan 15, 2007 In a preliminary ruling, Nice argued that Velcade, otherwise known as Bortezomib, ... Velcade is available in Scotland because the equivalent of Nice, ... Northern Echo - The Northern Echo … Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for... - Nov 1, 2007 US net sales of VELCADE grew 32 percent over the same period last year as we ... "Our increased financial guidance now projects that VELCADE US net sales ... $4.95 - PR Newswire - ECNext Cancer drug battle man has died - Feb 18, 2008 A cancer patient who fought a "postcode lottery" to be given the drug Velcade as part of his treatment has died. John McNamara, 47, from Harrogate, ... BBC News Suit seeks to win bragging rights for KU researchers - Nov 13, 2008 Velcade is a proteasome inhibitor widely used in the treatment of multiple myeloma. The drug is marketed by Millenium Pharmaceuticals Inc., which licensed ... $2.95 - Kansas City Star - NewsBank Millennium posts 1st profit in 7 years - Feb 9, 2007 Sales of Velcade, Millennium's only approved product, rose 5 percent to $55.1 ... Revenue rose for Velcade after US regulators expanded use of the drug in ... Boston Globe VELCADE Approved Across all Disease Stages for Broad Spectrum of … - Sep 8, 2008 HIGH WYCOMBE, England, September 8/PRNewswire/ --Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced the ... FierceBiotech Cancer Drug May Help With Kidney Transplants - Dec 29, 2008 29 (HealthDay News) -- The cancer drug bortezomib (Velcade) may also be effective at treating and reversing the rejection of transplanted kidneys, ... Washington Post … Foundation Reports New Drug Combination - Velcade(R) Plus Doxil(R)... - May 21, 2007 The combination of Doxil(R) with Velcade(R) provides nearly a three month improvement in time to disease progression as compared to Velcade alone, ... Genetic Engineering News - Genetic Engineering News (press release) FDA approves VELCADE plus DOXIL combination for multiple myeloma - May 23, 2007 Ortho Biotech Products has announced the US Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in ... News-Medical.net VELCADE(R) (bortezomib) for Injection Survival Data in Front-Line … - Jun 19, 2007 CAMBRIDGE, Mass., June 19 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that data for VELCADE, the market leading therapy with ... Free with registration - PR Newswire - AccessMyLibrary.com Drug Combo Aids Multiple Myeloma Patients - Dec 12, 2006 The patients were divided into groups that received successively higher doses of bortezomib (brand name Velcade) and lenalidomide (brand name Revlimid). ... Washington Post NICE set to confirm negative Velcade stand. - Oct 30, 2006 NICE set to confirm negative Velcade stand. The UK's National Institute for Health and Clinical Excellence (NICE) is set to confirm its draft appraisal on ... $9.94 - Pharma Marketletter - Alacra Store Buyout Talk Boosts Millennium - Jun 15, 2006 The takeover offer has ended, however, and Millennium says it's now planning to focus on expanding the sales of its blood cancer drug Velcade, ... TheStreet.com - TheStreet.com (subscription) Publications Feature VELCADE(R) (Bortezomib) For Injection Strength... - Dec 5, 2006 Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the publication of clinical data of VELCADE in the treatment of newly diagnosed multiple ... Medical News Today - Medical News Today (press release) Cancer sufferer wins drug battle - Jul 31, 2005 David Glass, 71, from Narborough, Leics, battled for months to get the Leicester Royal Infirmary to pay for Velcade, a therapy for bone cancer. ... BBC News … Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib)... - Jul 16, 2007 The trial, named UPFRONT and conducted primarily at community physician networks nationwide, will compare three VELCADE based therapies. ... RedOrbit Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In … - Feb 21, 2008 Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced the initiation of a multi-center, Phase II trial to evaluate VELCADE in combination with emerging ... Medical News Today - Medical News Today (press release) |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
